Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

17.57USD
1:18pm EDT
Change (% chg)

$0.22 (+1.27%)
Prev Close
$17.35
Open
$17.49
Day's High
$18.04
Day's Low
$17.44
Volume
320,972
Avg. Vol
360,825
52-wk High
$19.91
52-wk Low
$9.92

NKTR.OQ

Chart for NKTR.OQ

About

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $2,372.31
Shares Outstanding(Mil.): 136.73
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): -- 43.70 36.51
EPS (TTM): -0.97 -- --
ROI: -34.35 -0.32 13.85
ROE: -- -3.00 14.77

Bristol-Myers to test Opdivo with Nektar drug for several cancers

Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.

Sep 27 2016

BRIEF-Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration

* Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214

Sep 27 2016

BRIEF-Nektar Therapeutics reports Q2 loss per share $0.36

* Nektar Therapeutics reports financial results for the second quarter of 2016

Aug 03 2016

CORRECTED-BRIEF-Nektar Therapeutics, Daiichi Sankyo Europe sign licensing deal for breast cancer drug

* Nektar Therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments

Jun 01 2016

BRIEF-Nektar says co may pay Daiichi $12.5 mln termination payment

* In case of pre-conditional approval termination of deal, nektar would be obligated to pay daiichi a $12.5 million termination payment - sec filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 01 2016

BRIEF-Nektar Therapeutics reports Q1 loss per share $0.14

* Nektar therapeutics reports financial results for the first quarter of 2016

May 03 2016

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,858 -38.00
Eisai Co., Ltd (4523.T) ¥6,368 -99.00
NOF CORPORATION (4403.T) ¥1,020 +2.00
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs3,200.35 +9.65
Novo Nordisk A/S (NOVOb.CO) kr.290.00 +1.30
Pfizer Inc. (PFE.N) $33.72 -0.11
Novartis AG (NOVN.S) CHF78.55 +0.45
Roche Holding Ltd. (ROG.S) CHF244.60 +1.10
Roche Holding Ltd. (RO.S) CHF244.90 +0.80
GlaxoSmithKline plc (GSK.L) 1,655.00p +17.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.